1. A novel cardiovascular magnetic resonance risk score for predicting mortality following surgical aortic valve replacement
- Author
-
Vasiliki Tsampasian, Francisco Alpendurada, Marc R. Dweck, David E. Newby, Dominique Auger, Claire E. Raphael, Gary Tse, Dudley J. Pennell, Sanjay K Prasad, Miguel Silva Vieira, Menelaos Pavlou, Calvin W. L. Chin, John Pepper, Vassilios S. Vassiliou, Tamir Malley, Brian P Halliday, Russell J. Everett, Andrew Jabbour, and British Heart Foundation
- Subjects
Male ,medicine.medical_specialty ,Science ,Patient demographics ,Cardiology ,Magnetic Resonance Imaging, Cine ,Infarction ,Gadolinium ,Article ,Aortic valve replacement ,Internal medicine ,Humans ,Medicine ,Aged ,Aged, 80 and over ,Heart Valve Prosthesis Implantation ,Multidisciplinary ,Framingham Risk Score ,Ejection fraction ,Interventional cardiology ,medicine.diagnostic_test ,business.industry ,Stroke Volume ,Magnetic resonance imaging ,Aortic Valve Stenosis ,Middle Aged ,medicine.disease ,Survival Analysis ,United Kingdom ,Stenosis ,Treatment Outcome ,Risk factors ,Multivariate Analysis ,cardiovascular system ,Female ,business ,Platelet Aggregation Inhibitors - Abstract
The increasing prevalence of patients with aortic stenosis worldwide highlights a clinical need for improved and accurate prediction of clinical outcomes following surgery. We investigated patient demographic and cardiovascular magnetic resonance (CMR) characteristics to formulate a dedicated risk score estimating long-term survival following surgery. We recruited consecutive patients undergoing CMR with gadolinium administration prior to surgical aortic valve replacement from 2003 to 2016 in two UK centres. The outcome was overall mortality. A total of 250 patients were included (68 ± 12 years, male 185 (60%), with pre-operative mean aortic valve area 0.93 ± 0.32cm2, LVEF 62 ± 17%) and followed for 6.0 ± 3.3 years. Sixty-one deaths occurred, with 10-year mortality of 23.6%. Multivariable analysis showed that increasing age (HR 1.04, P = 0.005), use of antiplatelet therapy (HR 0.54, P = 0.027), presence of infarction or midwall late gadolinium enhancement (HR 1.52 and HR 2.14 respectively, combined P = 0.12), higher indexed left ventricular stroke volume (HR 0.98, P = 0.043) and higher left atrial ejection fraction (HR 0.98, P = 0.083) associated with mortality and developed a risk score with good discrimination. This is the first dedicated risk prediction score for patients with aortic stenosis undergoing surgical aortic valve replacement providing an individualised estimate for overall mortality. This model can help clinicians individualising medical and surgical care.Trial Registration ClinicalTrials.gov Identifier: NCT00930735 and ClinicalTrials.gov Identifier: NCT01755936.
- Published
- 2021